eXoZymes Prices $15M Unit Offering at Two Shares Plus One Five-Year Warrant, Pricing Still TBD
EXOZ sits 36% above its 52-week low of $3.24.
Summary
Three days after the S-1 registered up to $37.3M, eXoZymes' November 9 free writing prospectus sizes its underwritten offering at $15 million of units — two shares plus one five-year warrant each — with pricing still TBD.
Key Events · Financing and Capital Events · EXOZ
-
Offering Sized at $15 Million
The FWP sets the underwritten deal at $15 million of units, each unit two common shares plus one five-year warrant; pricing is still TBD.
-
Dilution Depends on Final Price
Against 9,304,701 common shares outstanding before the offering, $15M at today's $4.40 implies roughly 3.4M shares (about 37% of the pre-deal count), before warrant exercise — the actual figure moves with the offering price.
-
Underwriter Warrants Add Overhang
On top of the investor warrants, underwriter warrants equal 6% of shares sold in this offering.
-
Proceeds Earmarked Through 2028
Net proceeds of $13.95M ($15.0M gross less a 7% fee) are planned as $10.0M in 2027 and $3.95M in 2028, with $4.2M for NCT commercialization and scale-up.
Analysis · EXOZ · Life Sciences
Hard numbers now attach to the offering first registered on the November 6 S-1: $15 million of units, each unit two common shares plus one five-year warrant, with pricing still to come. For a company that carried a going-concern warning in its August 10-Q, this is survival capital rather than growth capital — and it lands on a small share base. The cap table shows 9,304,701 common shares outstanding before the deal, so $15 million at today's $4.40 would be roughly 3.4 million shares (about 37% of the pre-deal count), before counting the warrants. Where the deal actually prices will determine the real dilution, and the filing does not state it. Underwriters also take warrants equal to 6% of shares sold, adding further overhang.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXOZ was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $3.24 to $18.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.